Shanghai Jmt-bio Inc.

This study tests a new drug called JSKN003 against the usual treatment for HER2-positive breast cancer that has returned or spread. About 60 people who have not had prior therapy for advanced disease will be randomly assigned to receive either JSKN003 or a standard combination of…

This study tests whether a new drug called KN026, combined with chemotherapy and another drug (enlonstobart), works better than the current standard treatment for people with advanced HER2-positive stomach cancer. About 490 adults who have not had prior treatment for their advanc…

This study is testing a new drug called SYS6090, given together with chemotherapy or other targeted drugs, for people with advanced lung cancer that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors. About 596 adults aged 18…

This study tests a new drug called JSKN003 in people with advanced HER2-positive colorectal cancer that has not responded to standard chemotherapies. About 123 adults will receive either JSKN003 or a treatment chosen by their doctor. The goal is to see if JSKN003 can slow cancer …